期刊文献+

表皮生长因子受体在黑色素瘤紫杉醇耐药性中的机制研究 被引量:1

Mechanisms of epidermal growth factor receptor in paclitaxel resistance of melanoma
原文传递
导出
摘要 目的探究紫杉醇对黑色素瘤的作用机制及表皮生长因子受体(EGFR)信号通路在调节黑色素瘤侵袭与转移中的作用,揭示该信号通路与紫杉醇耐药的关系及相关机制。方法以EGFR高表达的恶性黑色素瘤A375细胞为研究对象,采用流式细胞术、细胞迁移实验、MTT法和蛋白质印迹法,研究紫杉醇及表皮生长因子(EGF)通过EGFR信号通路对A375细胞凋亡、增殖和迁移的影响。结果(1)细胞凋亡:紫杉醇诱导的A375细胞凋亡随浓度升高而增强(P<0.001),同时紫杉醇(0.1μmol/L)抑制Bcl-2并增加了Bax的表达(P<0.01);EGFR抑制剂AG1478可明显增加A375细胞凋亡并增强紫杉醇的诱导效果及对Bcl-2和Bax的影响(P<0.001);EGF单独处理对A375细胞凋亡无明显影响,但其可抑制紫杉醇诱导的细胞凋亡(P<0.05)及对Bcl-2和Bax的影响(P<0.001)。(2)细胞增殖:紫杉醇(0.1μmol/L)可显著抑制A375细胞增殖(P<0.001)且该作用可被AG1478进一步增强但被EGF减弱(P<0.001)。(3)细胞迁移:紫杉醇(0.1μmol/L)可显著抑制A375细胞的迁移(P<0.001),该抑制作用可被AG1478进一步增强但被EGF减弱(P<0.001)。结论紫杉醇能够降低Bcl-2并增加Bax表达,从而诱导黑色素瘤A375细胞的凋亡并抑制其增殖和迁移,而这些抑制作用可被EGF激活的EGFR通路减弱。 Objective To explore the mechanisms of paclitaxel on melanoma and the role of the epidermal growth factor receptor(EGFR)signaling pathway in regulating the invasion and metastasis of melanoma,and to reveal the relationship between the EGFR signaling pathway and paclitaxel resistance of melanoma cells.Methods Using malignant melanoma A375 cells with high EGFR expression,we utilized flow cytometry,Transwell assay,MTT,and Western blot to study the effects of paclitaxel and epidermal growth factor(EGF)on A375 cell apoptosis,proliferation,and migration.Results Paclitaxel induced apoptosis of A375 cells in a concentration-dependent manner(P<0.001).Meanwhile,paclitaxel(0.1μmol/L)inhibited Bcl-2 expression and increased the expression of Bax(P<0.01).EGFR inhibitor AG1478(20μmol/L)could significantly increase the apoptosis of A375 cells and enhance the apoptosis-inducing effect of paclitaxel(P<0.05)and its effect on Bcl-2 and Bax expression(P<0.001).EGF treatment alone had no significant effect on the apoptosis of A375 cells,but it could inhibit the apoptosis-inducing effect of paclitaxel(0.1μmol/L)as well as its effect on Bcl-2 and Bax(P<0.001).Paclitaxel(0.1μmol/L)inhibited the proliferation of A375 cells(P<0.001),which could be further enhanced by AG1478 but was inhibited by EGF(P<0.001).Paclitaxel(0.1μmol/L)inhibited the migration of A375 cells(P<0.001),which could be further enhanced by AG1478 but was decreased by EGF(P<0.001).Conclusion Paclitaxel can reduce Bcl-2 expression but increase the expression of Bax,thereby inducing the apoptosis of melanoma A375 cells and inhibiting their proliferation and migration.However,these inhibitory effects can be weakened by EGF via the EGFR pathway.
作者 陈文静 唐乙厶 赵蓓 徐敏燕 李涛 Chen Wenjing;Tang Yisi;Zhao Bei;Xu Minyan;Li Tao(Institute of Dermatology and Venereology,Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital(Affiliated Hospital of UESTC),Chengdu 610000,China)
出处 《中华临床医师杂志(电子版)》 CAS 北大核心 2022年第1期94-99,共6页 Chinese Journal of Clinicians(Electronic Edition)
基金 四川省科技厅省级科研院所基本科研业务项目(2018YSKY0017-11)。
关键词 黑色素瘤 紫杉醇 表皮生长因子 表皮生长因子受体 细胞凋亡 Melanoma Paclitaxel Epidermal growth factor Epidermal growth factor receptor Apoptosis
  • 相关文献

参考文献3

二级参考文献32

  • 1Hai-feng Song,Xiu-wen Liu,Hai-ning Zhang,Bao-zhen Zhu,Shou-jun Yuan,Shang-yi Liu,Zhong-ming Tang.Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys[J].Acta Pharmacologica Sinica,2005,26(1):124-128. 被引量:16
  • 2王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:625
  • 3Gradishar WJ. Albumin-bound paclitaxel: a next- generation taxane [J].Expert Opin Pharmacother, 2006, 7(1): 1041-1053.
  • 4Melanoma. Version 1.2015. NCCN Clinical Practice Guidelines in Oneology [OL]. http://www.nccn.org/ professionals/physician_gls/pdf/melanoma.pdf.
  • 5Hersh E, Millward M, Elias I, et al. An open-label, multicenter, phase III trial of nab-paclitaxel (NP) versus dacarbazine (DTIC) in previously untreated patients (PTs) with metastatic malignant melanoma (MMM) [J/OL]. J Clin Oncol,2010,28:15s. 2010 (suppl ; abstr TPS314). http ://meeting.ascopubs.org/ cgi/content/abstract/28/15 suppl/TPS314 ? sid = 7d58a73b-bf85-41 a0-80fb-4a4a2a66abOf.
  • 6Sampsel JW, Barbera-Guillem E. Management of cutaneous melanoma [J]. N Engl J Med, 2004, 351 (26) : 2770-1.
  • 7Korn EL, Liu PY, Lee S J, et al. Meta-analysis of phase 1I cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials [J]. J Clin Oncol, 2008, 26(4): 527-34.
  • 8McDermott D, Haanen J, Chen Tr, et al. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)[J]. Ann Oncol, 2013, 24 (10) :2694-2698.
  • 9Catalanotti F, Solit DB, Pulitzer MP, et al. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY- 142886) in patients with BRAFV600E/K-mutated melanoma[J]. Clin Cancer Res, 2013, 19(8) : 2257-2264.
  • 10Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma [J]. J Clin Oncol, 2013, 31(26) :3205-3211.

共引文献17

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部